Geron Corporation

University of Colorado

Other

Telomerase Activation Sciences, Inc.

University of Texas System

University of California

Telomere Diagnostics, Inc.

Mcmaster University

University Technology Corporation

Geron Corporation & Board of Regents

Telomerase Activation Science, Inc.

Calvin B Harley

William H Andrews

Thomas R Cech

Gregg B Morin

Karen B Chapman

Joachim Lingner

Toru M Nakamura

Scott L Weinrich

Nam Woo Kim

Michael D West

Jerry W Shay

Woodring E Wright

Tsutomu Akama

Laurence Elias

Mahesh Ramaseshan

Premchandran H Ramiya

Soo-Peang Khor

Mark J Ratain

Elizabeth H Blackburn

Allison C Chin

Zhu Zhen Pirot

Homayoun Vaziri

Michael J McEachern

Tong Lin

Steven Fauce

Catherine M Strahl

Nancy Yuk-yu Ip

Yung-hou Wong

David M Miller-Martini

Jennifer Smith

Fabio Benedetti

Jue Lin

Karl J Guegler

Nam Hoon Kim

Bryant Villeponteau

Nancy Yuk-Yu Ip

Choy-Pik Chiu

Silvia Bacchetti

Brian Leber

Christopher M Counter

Yajing Hu

Xu-Rong Jiang

Yung-Hou Wong

Yung-Hou Phd Associate Professor Dept Of Biolochemistry Wong

Cregg B Morin

William H c/o Serra Sciences Inc Andrews

This invention provides methods and materials for measuring telomere abundance from chromosomes in a sample having telomeres within a pre-determined length range, e.g., short telomeres up to a certain length. The methods can involve a first step of performing a time-limited extension reaction calibrated to produce extension products from a double-stranded chromosomal DNA template of no more than a defined length, and a second step of amplifying, from the extension products, sequences bounded by a sub-telomeric sequence and the anchor sequence, to produce a length-limited telomere sequence product. The abundance of telomeric sequences in this product can be measured, and the measures can be correlated to a variety of indices.

Measures of short telomere abundance

The invention provides methods for determining the susceptibility of cancer patients to developing adverse reactions if treated with a telomerase inhibitor drug by measurement of telomere length in appropriate cells of the patient prior to initiation of the telomerase inhibitor treatment.

Method for identification of sensitivity of a patient to telomerase inhibition therapy

Disclosed are methods and compositions for determining the average length or abundance of a first target nucleic by calculating the abundance of a first target nucleic acid (T) relative to the average abundance (S) of a second and a third target nucleic acid, in a single well using a separate detection label for each target nucleic acid. In various aspects, the first target nucleic acid is a telomere. In exemplary aspects, the disclosed methods and compositions can be used to determine the average telomere length in a biological sample. The average telomere length determined using the disclosed methods and compositions can be correlated to a variety of clinically important conditions and indices. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Multiplex quantitative PCR

The present invention relates to methods and compositions for increasing telomerase activity in cells. Such compositions include pharmaceutical formulations. The methods and compositions are useful for treating diseases subject to treatment by an increase in telomerase activity in cells or tissue of a patient. They are also useful for enhancing replicative capacity of cells in culture, as in ex vivo cell therapy and for enhancing proliferation of stem and progenitor cells.

Compositions and methods for increasing telomerase activity

Methods and cosmetic compositions for conditioning the skin, utilizing as active ingredients selected compounds structurally related to astragenols, cycloastragenols, and/or protopanaxatriols, are provided. Such compounds include those of formulas (I), (II) and (III) described herein.

Compositions and methods for skin conditioning

The present invention relates to methods and compositions for increasing telomerase activity in cells. Such compositions include pharmaceutical, including topical, and nutraceutical formulations. The methods and compositions are useful for treating diseases subject to treatment by an increase in telomerase activity in cells or tissue of a patient, such as, for example, HIV infection, various degenerative diseases, and acute or chronic skin ailments. They are also useful for enhancing replicative capacity of cells in culture, as in ex vivo cell therapy and proliferation of stem cells.

The invention provides compositions and methods related to human telomerase reverse transcriptase (hTRT), the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers.

Method for eliciting an immune response to human telomerase reverse transcriptase

Human telomerase catalytic subunit

Kit for detection of telomerase reverse transcriptase nucleic acids

The present invention relates to methods for increasing telomerase activity in cells. Such compositions include pharmaceutical, including topical, and nutraceutical formulations. The method and compositions are useful for treating diseases subject to treatment by an increase in telomerase activity in cells or tissue of a patient, such as, for example, HIV infection, various degenerative diseases, and acute or chronic skin aliments. They are also useful for enhancing replicative capacity of cells in culture, as in ex vivo cell therapy and proliferation of stem cells.

Antibody to telomerase reverse transcriptive

Growing community of inventors

Palo Alto, CA, United States of America

Calvin B Harley